U.S. Machinery Stock News

Why Simone Lagomarsino’s Board Appointment Matters For Columbia Banking System Columbia Banking System (COLB) has drawn investor attention after announcing that Simone Lagomarsino will join its Board of Directors on September 1, 2026, with roles on the Enterprise Risk Management and Audit Committees. For a regional bank that operates entirely in the United States, this kind of board change can shape how the company thinks about risk, growth opportunities and oversight. Investors often watch...

Cavco Industries, Inc. reported first-quarter 2027 results on July 30, 2026, with sales rising to US$585.97 million from US$535.69 million a year earlier, while net income and earnings per share declined, and the company continued executing on its share repurchase program. Alongside record revenue and a roughly 50% expansion in backlog that points to strong demand, Cavco’s outlook is being shaped by the recently passed bipartisan ROAD to Housing Act, which is expected to support manufactured...

IDEAYA Biosciences recently reported second-quarter 2026 results, posting US$8.86 million in revenue alongside a wider net loss of US$112.45 million, or US$1.22 per share, while also updating investors on its development programs. A key highlight was the advance of IDE892 into Part 2 monotherapy expansion in its Phase 1/2 trial for MTAP-deleted solid tumors, underscoring progress in an area where there are currently no approved therapies. Against this backdrop, we’ll examine how IDE892’s...

Quanta Services stock has delivered a very large 5 year return, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiple checks currently point to the shares trading at a premium rather than offering clear value. Quanta Services has returned very close to 6x over the past 5 years, which puts extra focus on whether today’s price still offers an attractive entry point. Stronger revenue growth expectations after recent acquisitions can support a higher valuation,...

In recent days, American Eagle Outfitters reported that analysts expect upcoming earnings to show a lower EPS but higher revenue than a year ago, alongside a forward P/E ratio below the industry average and a Zacks Rank #2 (Buy) rating that was assigned before today. This combination of revenue growth expectations, compressed valuation multiples, and favorable analyst ranking has become a focal point for investors reassessing the retailer’s earnings power and positioning in the specialty...

In late July 2026, UniCredit announced a long‑term collaboration with Accenture and IBM to redesign its banking technology model across thirteen European markets, including Accenture acquiring IBM’s majority stake in their joint technology infrastructure joint venture, while IBM supplies modernised platforms like IBM Z, software and consulting, subject to regulatory approvals. A few days earlier, Radisson Hotel Group revealed it had partnered with Accenture to launch an AI-powered hotel...

Affirm Holdings has delivered a very strong 396.4% return over the past three years. However, current valuation checks and the Excess Returns intrinsic value estimate both indicate the stock is trading at a premium to what the fundamentals support. A roughly 396.4% gain over three years highlights how sharply expectations for Affirm Holdings have reset. This raises the bar for what the business needs to deliver next. Expectations for continued growth in Affirm Holdings' buy now, pay later...

Tempus AI (TEM) is back in focus after CellCarta added the company to its CDx Commercialization Lab Network, linking Tempus Hub ordering to CellCarta testing and tightening access to oncology companion diagnostics for U.S. providers. See our latest analysis for Tempus AI. Tempus AI’s recent CellCarta partnership, PRISM2 publication and earnings update have arrived alongside a sharp 1-day share price return of 12.86% and a 7-day share price return of 18.65%. However, the year-to-date share...

Rithm Capital (RITM) reported second quarter 2026 results that gave investors fresh insight into the real estate focused asset manager. Sales reached US$182.13 million and net income was US$56.29 million. See our latest analysis for Rithm Capital. Following the second quarter update, Rithm Capital's share price sits at US$10.19, with a 30 day share price return of 11% and a year to date share price decline of 7.19%, while the 5 year total shareholder return of 69.07% highlights a stronger...

With global food prices sitting at multi year highs in July 2026, many investors are watching headline inflation and missing a quieter story. Lower used car prices and easing inflation in several countries are pointing to gentler price pressures. That can put more attention on companies where cash flows matter most. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that stand out today. The three stocks highlighted below are just a sample. The full...

On August 6, 2026, US Foods Holding Corp. reported higher second-quarter and year-to-date sales and net income, reaffirmed its 2026 net sales growth guidance of 4% to 6%, and completed share repurchases totaling 16,612,155 shares for about US$1.36 billion across two buyback authorizations. The combination of improved earnings, ongoing confidence in full-year performance, and sizable buybacks shrinking the share count highlights management’s focus on both operational execution and capital...

Astera Labs, Inc. reported past second-quarter 2026 results showing sales of US$392.4 million and net income of US$153.09 million, alongside six-month sales of US$700.76 million and net income of US$233.4 million, all substantially higher than a year earlier. Alongside these results, the company issued upbeat third-quarter 2026 guidance, projecting US$540 million to US$560 million in revenue and GAAP diluted EPS of US$0.87 to US$0.92, underscoring management’s confidence in its current AI...

Arcutis Biotherapeutics (ARQT) is back on investor radars after second quarter 2026 results showed revenue of $129.86 million, net income of $15.01 million, and raised full year net product sales guidance. See our latest analysis for Arcutis Biotherapeutics. The latest results and raised full year guidance have come alongside a 19.07% 3 month share price return and a 71.23% 1 year total shareholder return. However, shorter term share price returns over the past month and year to date have...

Why Avery Dennison Stock Is Back in Focus After Q2 Avery Dennison (AVY) is drawing fresh attention after reporting higher Q2 2026 sales and net income, lifting its full-year earnings guidance, continuing its share buyback program, and declaring a new cash dividend. See our latest analysis for Avery Dennison. Avery Dennison’s recent Q2 earnings beat, higher full year guidance, share buybacks and the new dividend have coincided with a 10.25% 1 month share price return and a 6.08% 1 year total...

Dow (DOW) is in focus after SweetNight selected the company and GoodBed to run independent mattress testing and consumer education, aiming to provide clearer performance data and build trust in mattress purchases. See our latest analysis for Dow. Dow's latest mattress testing partnership comes against a mixed share price backdrop, with the stock down 24.3% over the past 90 days, yet showing a 20.9% year to date share price return and a 45.5% 1 year total shareholder return. This points to...

In late July 2026, Crane Company reported second-quarter 2026 results showing sales rising to US$724.7 million and net income of US$95.9 million, alongside affirming a regular quarterly dividend of US$0.255 per share for payment on September 9, 2026. The company also raised its full-year 2026 sales growth guidance into the mid-20% range, highlighting acquisitions as a key driver of its expanded outlook. Now we’ll explore how Crane’s raised full-year sales guidance, driven by acquisitions,...

With the S&P 500 at record highs and valuations flashing similar signals to the late 1990s, many investors worry about where the next painful reset might land. Yet this is also when quality can matter most, as resilient dividend payers may stand out if lofty growth stories disappoint. This article walks through three stocks exposed to today’s AI driven enthusiasm and rich valuations, all drawn from a High-Quality Dividend Growth Stocks screener. The stocks covered below are just a starting...

Ashland Inc. previously declared a quarterly cash dividend of US$0.42 per share, payable on September 15, 2026, to shareholders of record on September 1, 2026, alongside reporting third-quarter fiscal 2026 sales of US$497 million and net income of US$16 million. The company also reached a cooperation agreement with Ancora Holdings Group, adding two independent directors and forming a Capital Allocation Advisory Committee, potentially reshaping how Ashland thinks about investment priorities...

In the past quarter, Ligand Pharmaceuticals reported second-quarter 2026 revenue of US$63.69 million, up from US$47.63 million a year earlier, with net income rising to US$48.51 million and diluted earnings per share from continuing operations reaching US$2.22. For the first half of 2026, Ligand moved from a net loss to net income and reaffirmed its full-year outlook for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring a...

Nearshoring to Mexico has quietly reshaped how North American electronics and advanced manufacturing reach the U.S. market, with USMCA rules and tariff pressures on China pushing more tech supply chains south of the border. For investors, that shift creates a fresh set of potential winners and risks across hardware, chip and AI related manufacturing stocks. This article walks through three stocks from our screener that appear closely tied to this story today. The three stocks that follow are...

In late July 2026, PC Connection, Inc. reported second-quarter sales of US$854 million and net income of US$33.17 million, with earnings per share rising year on year, and the Board declared a US$0.20 quarterly dividend payable on August 28, 2026. The company highlighted record results supported by strong demand for enterprise AI solutions and technology modernization, including Windows 11 migrations, alongside record backlogs that underpin its operational momentum. We’ll now examine how...

In the second quarter of 2026, Adaptive Biotechnologies reported sales of US$71.55 million, higher than a year earlier, alongside a wider net loss of US$39.79 million and a basic loss per share from continuing operations of US$0.25. Alongside these results, the company raised full-year 2026 revenue guidance for its MRD business to a range of US$268 million to US$278 million, signaling increased management confidence in that segment despite ongoing losses. Now, we will assess how the upgraded...

Fox stock has almost doubled over the past three years, and after that kind of run the current share price near US$64 no longer looks obviously cheap or obviously expensive. The Discounted Cash Flow (DCF) intrinsic value estimate points to a price that is close to fair value, while the broader valuation checks and market multiples leave room for debate about how much upside is left. Fox has returned about 92.2% over the past three years, which puts recent gains at the center of any valuation...

Accel Entertainment (ACEL) is attracting fresh attention after its 4 August 2026 earnings update, which showed higher sales, revenue and net income for both the quarter and first half compared with the prior year. See our latest analysis for Accel Entertainment. At a share price of $12.16, Accel Entertainment has posted a 6.95% year to date share price return and a 10.34% 1 year total shareholder return, which suggests moderate positive momentum heading into the latest earnings and capital...